Changes in pelvic active bone marrow seen on FDG-PET in patients receiving concurrent chemoradiation for anal cancer

Changes in pelvic active bone marrow seen on FDG-PET in patients receiving concurrent chemoradiation for anal cancer

Bibliographic Details
Main Authors:	Robinson, M, Virdee, P, Strauss, V, Cooke, R, Ng, S, Van Den Heuvel, F, Jacobs, C, Muirhead, R, Hawkins, M
Format:	Conference item
Published:	Elsevier 2018

Similar Items

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
by: Robinson, M, et al.
Published: (2019)

Is there a role for an FDG derived biological boost in squamous cell anal cancer?
by: Sabbagh, A, et al.
Published: (2018)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
by: John M. David, MD, et al.
Published: (2019-10-01)

Is there a role for a biological boost in squamous cell anal cancer?
by: Sabbagh, A, et al.
Published: (2018)

Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer
by: Robinson, M, et al.
Published: (2015)

Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation
by: Pierfrancesco Franco, et al.
Published: (2017-11-01)

Is there a role for an 18F-fluorodeoxyglucose-derived biological boost in squamous cell anal cancer?
by: Sabbagh, A, et al.
Published: (2018)

Concurrent Chemoradiation in Anal Cancer Patients Delivered with Bone Marrow-Sparing IMRT: Final Results of a Prospective Phase II Trial
by: Francesca Arcadipane, et al.
Published: (2021-05-01)

Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation
by: Kumar T, et al.
Published: (2019-07-01)

Efficacy Of 18FDG-PET/CT In Predicting Response After Neoadjuvant Chemoradiation In Rectal Cancer
by: Narendra Pandit, et al.
Published: (2023-08-01)

Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer
by: Maelle Le Thiec, et al.
Published: (2020-06-01)

Intestinal FDG-PET/CT imaging of an Eritrean with schistosomiasis seen in Denmark
by: Ata Daghigh, et al.
Published: (2019-10-01)

Concurrent chemoradiation for vaginal cancer.
by: David T Miyamoto, et al.
Published: (2013-01-01)

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma
by: Athénaïs Grave, et al.
Published: (2022-07-01)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
by: Casadei-Gardini A, et al.
Published: (2019-04-01)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]
by: Casadei-Gardini A, et al.
Published: (2019-06-01)

Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT)
by: Durrant, L, et al.
Published: (2016)

Predictive Role of MRI and <sup>18</sup>F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study
by: Anna Myriam Perrone, et al.
Published: (2020-03-01)

"CONCURRENT CHEMORADIATION FOR ESOPHAGEAL CARCINOMA: PRELIMINARY RESULTS"
by: MM. Merati SM. Sajjadi, et al.
Published: (2004-08-01)

"CONCURRENT CHEMORADIATION FOR ESOPHAGEAL CARCINOMA: PRELIMINARY RESULTS"
by: P. Haddad, et al.
Published: (2004-06-01)

Cisplatin-induced ototoxicity in patients receiving concurrent chemoradiation in carcinoma cervix
by: Hanan M, et al.
Published: (2022-07-01)

Predictors of Acute Hematologic Toxicity in Women Receiving Extended-Field Chemoradiation for Cervical Cancer: Do Known Pelvic Radiation Bone Marrow Constraints Apply?
by: Jared H.L. Hara, MD, et al.
Published: (2022-11-01)

A tumor control probability model for anal squamous cell carcinoma
by: Muirhead, R, et al.
Published: (2015)

Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer
by: Warren, S, et al.
Published: (2017)

FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma
by: Cannillo Barbara, et al.
Published: (2010-02-01)

Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
by: Romain-David Seban, et al.
Published: (2019-05-01)

A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation
by: Yimin Li, et al.
Published: (2020-10-01)

Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer
by: Feiya Shi, et al.
Published: (2022-03-01)

Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma
by: Bluemke, E, et al.
Published: (2020)

Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
by: Shakir, R, et al.
Published: (2019)

FDG-PET/CT in the Radiotherapy Treatment Planning of Locally Advanced Anal Cancer: A Monoinstitutional Experience
by: Clelia Di Carlo, et al.
Published: (2021-07-01)

Treatment outcome after radiochemotherapy in anal cancer patients staged with 18F-FDG-PET-CT
by: L.H. Braun, et al.
Published: (2020-09-01)

Pelvic Actinomycosis Associated with an Intrauterine Contraceptive Device Demonstrated on F-18 FDG PET/CT
by: Danijela Dejanović, et al.
Published: (2015-08-01)

Diagnostic Value of FDG PET/MRI in Females With Pelvic Malignancy—A Systematic Review of the Literature
by: Nghi Co Nguyen, et al.
Published: (2020-09-01)

Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
by: Crowley, C, et al.
Published: (2009)

Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
by: Crowley, C, et al.
Published: (2009)

A Rare Case of New-Onset Atrial Fibrillation Presenting as Biatrial Inflammation Seen on 18F-FDG-PET
by: Rachad Ghazal, MD, et al.
Published: (2023-12-01)

FDG-PET parameters predict for recurrence in anal cancer – results from a prospective, multicentre clinical trial
by: Michael Peter Jones, et al.
Published: (2019-08-01)

Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.
by: Julian Kirchner, et al.
Published: (2017-01-01)

PET-FDG: Impetus
by: Cristina Nanni
Published: (2020-04-01)